Summary
Emerging targeted therapies have broadened treatment options for patients with advanced non–small cell lung cancer (advNSCLC), however, overall survival (OS), the gold standard in efficacy studies, requires an extended follow-up period and may be immature when other data options are available. This study aimed to estimate the relationship between EHR-derived real-world progression free survival (rwPFS) and real-world overall survival (rwOS) in patients with ROS1+ advNSCLC in a real-world setting.
Assessing nearly 400 patients with ROS1+ advNSCLC who received treatment between 2011 and 2023, 52% of the cohort received ROS1 tyrosine-kinase inhibitors, which is the current standard of care, and their median rwOS and rwPFS were 29.1 months and 8.6 months, respectively. It was seen that patients who progressed within the first 6, 12, and 18 months had a significantly higher risk of death compared to patients who did not progress.
Why this matters
This research suggests that rwPFS can potentially be a predictor of rwOS, reducing timelines to study efficacy in emerging treatments for advanced lung and other cancers. This research will enable further use of real-world evidence to understand what treatments are working for patients when, however, more research is needed to confirm how well rwPFS can stand-in for rwOS in clinical trials and practice.